Related Experiment Video
Updated: May 13, 2026
Candida albicans Biofilm Development on Medically-relevant Foreign Bodies in a Mouse Subcutaneous Model Followed by Bioluminescence Imaging
Published on: January 27, 2015
Reevaluating the Value of (1,3)-β-D-Glucan for the Diagnosis of Intra-Abdominal Candidiasis in Critically Ill
Emmanuel Novy1,2, Mathieu Esposito1, Anne Debourgogne2,3
1Department of Anesthesiology, Critical Care and Perioperative Medicine, Surgical Intensive Care Unit, CHRU-Nancy, F-54000 Nancy, France.
Abstract:
Intra-abdominal candidiasis (IAC) is associated with significant diagnostic and therapeutic challenges in critically ill patients. Traditional fungal cultures are slow, delaying appropriate antifungal treatment. (1,3)-β-D-glucan (BDG), a component of the fungal cell wall, has emerged as a potential biomarker for IAC, but its use in ICU settings is complicated by frequent false-positives results from invasive procedures and underlying conditions. This review examines the diagnostic value of BDG when present in serum and peritoneal fluid. While serum BDG is effective for excluding invasive fungal infections like candidemia, its specificity for IAC remains low in critically ill patients. Recent studies suggest that BDG levels in peritoneal fluid may provide better diagnostic accuracy, distinguishing IAC from bacterial peritonitis with higher specificity. We discuss the advantages, limitations, and practical aspects of BDG testing, emphasizing the potential of peritoneal BDG as a complementary tool. Further research is needed to refine diagnostic thresholds, validate its clinical utility, and establish the role of peritoneal BDG in improving timely, targeted antifungal treatment for IAC.
Insights
Peritoneal fluid (1,3)-β-D-glucan (BDG) shows promise for diagnosing intra-abdominal candidiasis (IAC) in critically ill patients. Serum BDG is less specific for IAC, but peritoneal BDG may help differentiate fungal from bacterial infections.
Area of Science:
- Critical Care Medicine
- Mycology
- Clinical Diagnostics
Background:
- Intra-abdominal candidiasis (IAC) presents diagnostic and treatment challenges in critically ill patients.
- Conventional fungal cultures are slow, delaying essential antifungal therapy.
- (1,3)-β-D-glucan (BDG) is a fungal cell wall biomarker with potential for IAC diagnosis, but its utility is limited by false positives in intensive care unit (ICU) settings.
Purpose of the Study:
- To review the diagnostic value of BDG in serum and peritoneal fluid for intra-abdominal candidiasis (IAC).
- To assess the potential of peritoneal BDG as a diagnostic tool for IAC in critically ill patients.
Main Methods:
- Systematic review of studies evaluating BDG in serum and peritoneal fluid for IAC diagnosis.
- Analysis of BDG performance in differentiating IAC from other conditions, including bacterial peritonitis and candidemia.
- Discussion of practical aspects, advantages, and limitations of BDG testing in ICU patients.
Main Results:
- Serum BDG effectively excludes candidemia but shows low specificity for diagnosing IAC in critically ill patients.
- Peritoneal fluid BDG demonstrates higher specificity in distinguishing IAC from bacterial peritonitis.
- Current data suggest peritoneal BDG may serve as a valuable complementary diagnostic marker for IAC.
Conclusions:
- Peritoneal fluid BDG offers improved diagnostic accuracy for IAC compared to serum BDG in critically ill patients.
- Further research is required to establish optimal diagnostic thresholds and clinical utility of peritoneal BDG.
- Peritoneal BDG holds potential to enhance timely and targeted antifungal treatment for intra-abdominal candidiasis.
